NASDAQ:BLUE bluebird bio (BLUE) Stock Price, News & Analysis → Never use this word on your phone (FBI could be watching) (From Paradigm Press) (Ad) Free BLUE Stock Alerts $0.90 0.00 (0.00%) (As of 05/3/2024 ET) Add Compare Share Share Today's Range$0.89▼$0.9450-Day Range$0.89▼$1.7552-Week Range$0.86▼$5.53Volume7.10 million shsAverage Volume6.13 million shsMarket Capitalization$98.38 millionP/E RatioN/ADividend YieldN/APrice Target$5.74 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get bluebird bio alerts: Email Address bluebird bio MarketRank™ Stock AnalysisAnalyst RatingHold2.27 Rating ScoreUpside/Downside538.4% Upside$5.74 Price TargetShort InterestBearish29.83% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.13Based on 12 Articles This WeekInsider TradingSelling Shares$4,134 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.72) to ($1.07) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.16 out of 5 starsMedical Sector3187th out of 5,424 stocksBiological Products, Except Diagnostic Industry508th out of 909 stocks 3.1 Analyst's Opinion Consensus Ratingbluebird bio has received a consensus rating of Hold. The company's average rating score is 2.27, and is based on 4 buy ratings, 6 hold ratings, and 1 sell rating.Amount of Analyst Coveragebluebird bio has only been the subject of 4 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted29.83% of the outstanding shares of bluebird bio have been sold short.Short Interest Ratio / Days to Coverbluebird bio has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in bluebird bio has recently increased by 9.65%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend Yieldbluebird bio does not currently pay a dividend.Dividend Growthbluebird bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BLUE. Previous Next 1.7 News and Social Media Coverage News Sentimentbluebird bio has a news sentiment score of 0.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.43 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for bluebird bio this week, compared to 6 articles on an average week.Search InterestOnly 30 people have searched for BLUE on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.MarketBeat FollowsOnly 13 people have added bluebird bio to their MarketBeat watchlist in the last 30 days. This is a decrease of -46% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, bluebird bio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,134.00 in company stock.Percentage Held by InsidersOnly 2.10% of the stock of bluebird bio is held by insiders.Percentage Held by Institutions87.43% of the stock of bluebird bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for bluebird bio are expected to grow in the coming year, from ($1.72) to ($1.07) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of bluebird bio is -1.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of bluebird bio is -1.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share Ratiobluebird bio has a P/B Ratio of 0.38. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Colonial MetalsThe Gold Grab of the CenturyWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.That's why we have released our Free Precious Metals Investment Guide. About bluebird bio Stock (NASDAQ:BLUE)bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.Read More BLUE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BLUE Stock News HeadlinesMay 3, 2024 | prnewswire.comSHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of BlueMay 3, 2024 | prnewswire.comClass Action Filed Against bluebird bio, Inc. (BLUE) - May 28, 2024 Deadline to Join - Contact The Gross Law FirmMay 4, 2024 | Paradigm Press (Ad)Never use this word on your phone (FBI could be watching)This report sent a chill down my spine. Turns out, as part of their Jan. 6th investigation, the Feds are flagging Americans who typed these ordinary words as part of their banking transactions...May 3, 2024 | msn.comSweetwater's big fourth inning carries them past Polk CountyMay 2, 2024 | prnewswire.comBLUE Investors Have Opportunity to Lead bluebird bio, Inc. Securities Fraud LawsuitMay 2, 2024 | americanbankingnews.combluebird bio, Inc. (NASDAQ:BLUE) Short Interest UpdateMay 1, 2024 | markets.businessinsider.comROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages bluebird bio Inc. Investors to Inquire About Securities Class Action Investigation - BLUEMay 1, 2024 | prnewswire.comSHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in bluebird bio, Inc. with Losses of $100,000 to Contact the FirmMay 4, 2024 | Paradigm Press (Ad)Never use this word on your phone (FBI could be watching)This report sent a chill down my spine. Turns out, as part of their Jan. 6th investigation, the Feds are flagging Americans who typed these ordinary words as part of their banking transactions...April 29, 2024 | prnewswire.comBLUE Investors Have Opportunity to Lead bluebird bio, Inc. Securities Fraud LawsuitApril 29, 2024 | prnewswire.comBLUE INVESTOR NOTICE: ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages bluebird bio Inc. Investors to Inquire About Securities Class Action Investigation - BLUEApril 28, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against bluebird bio, Inc. - BLUEApril 27, 2024 | prnewswire.comBLUE INVESTOR NEWS: TOP RANKED ROSEN LAW FIRM Encourages bluebird bio Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BLUEApril 27, 2024 | markets.businessinsider.comONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of bluebird bioApril 27, 2024 | stockhouse.comBLUE LOSS ALERT: TOP RANKED ROSEN LAW FIRM Encourages bluebird bio Inc. Investors to Inquire About Securities Class Action Investigation - BLUEApril 26, 2024 | businesswire.combluebird bio Announces Receipt of Expected Notice from NasdaqApril 26, 2024 | prnewswire.comBLUE LAWSUIT ALERT: The Gross Law Firm Notifies bluebird bio, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineApril 26, 2024 | prnewswire.comBLUE LAWSUIT ALERT: The Gross Law Firm Notifies bluebird bio, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineApril 25, 2024 | prnewswire.comSHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of BlueApril 24, 2024 | stockhouse.comBLUE Equity Alert: ROSEN, A Top Ranked Law Firm, Encourages bluebird bio Inc. Investors to Inquire About Securities Class Action Investigation - BLUEApril 24, 2024 | prnewswire.comBLUE Investors Have Opportunity to Lead bluebird bio, Inc. Securities Fraud LawsuitApril 23, 2024 | money.usnews.comBluebird bio IncApril 23, 2024 | prnewswire.comSHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in bluebird bio, Inc. with Losses of $100,000 to Contact the FirmApril 22, 2024 | prnewswire.comLost Money on bluebird bio, Inc.(BLUE)? Join Class Action Suit Seeking Recovery - Contact Levi & KorsinskyApril 21, 2024 | markets.businessinsider.comROSEN, National Trial Lawyers, Encourages bluebird bio Inc. Investors to Inquire About Securities Class Action Investigation - BLUEApril 20, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against bluebird bio, Inc. - BLUEApril 19, 2024 | stockhouse.comINVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in bluebird bio, Inc. with Losses of $100,000 to Contact the FirmSee More Headlines Receive BLUE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for bluebird bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/07/2023Today5/04/2024Next Earnings (Estimated)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:BLUE CUSIPN/A CIK1293971 Webwww.bluebirdbio.com Phone(339) 499-9300FaxN/AEmployees323Year FoundedN/APrice Target and Rating Average Stock Price Target$5.74 High Stock Price Target$13.00 Low Stock Price Target$1.02 Potential Upside/Downside+538.4%Consensus RatingHold Rating Score (0-4)2.27 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)($0.74) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-266,580,000.00 Net Margins-419.64% Pretax Margin-419.50% Return on Equity-34.32% Return on Assets-14.44% Debt Debt-to-Equity RatioN/A Current Ratio1.55 Quick Ratio1.42 Sales & Book Value Annual Sales$3.60 million Price / Sales27.33 Cash FlowN/A Price / Cash FlowN/A Book Value$2.37 per share Price / Book0.38Miscellaneous Outstanding Shares109,340,000Free Float107,040,000Market Cap$98.38 million OptionableOptionable Beta0.82 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Andrew Obenshain (Age 50)President, CEO & Director Comp: $1.04MMr. Thomas J. Klima (Age 52)Chief Commercial Officer & COO Comp: $654.97kMr. Richard A. Colvin M.D. (Age 58)Ph.D., Chief Medical Officer Comp: $696.24kMr. Christopher Krawtschuk CPA (Age 50)CFO, Principal Accounting Officer & Treasurer Mr. Joseph D. Vittiglio Esq. (Age 52)J.D., Chief Legal & Business Officer and Secretary Jess RowlandsHead of Corporate CommunicationsMs. Andrea WaltonChief People OfficerMr. Kasra KasraianSenior Vice President of Technical Development & OperationsMr. Scott ShoemakerSenior Vice President of QualityMs. Sarah AlspachSenior Vice President of External AffairsMore ExecutivesKey CompetitorsVigil NeuroscienceNASDAQ:VIGLAlloVirNASDAQ:ALVRCurisNASDAQ:CRISaTyr PharmaNASDAQ:LIFESangamo TherapeuticsNASDAQ:SGMOView All CompetitorsInsiders & InstitutionsMirae Asset Global Investments Co. Ltd.Bought 90,139 shares on 5/1/2024Ownership: 0.297%BNP Paribas Financial MarketsSold 422,863 shares on 5/1/2024Ownership: 0.093%Sequoia Financial Advisors LLCBought 13,000 shares on 5/1/2024Ownership: 0.037%China Universal Asset Management Co. Ltd.Bought 23,933 shares on 4/29/2024Ownership: 0.033%Enterprise Bank & Trust CoBought 30,000 shares on 4/10/2024Ownership: 0.027%View All Insider TransactionsView All Institutional Transactions BLUE Stock Analysis - Frequently Asked Questions Should I buy or sell bluebird bio stock right now? 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for bluebird bio in the last year. There are currently 1 sell rating, 6 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" BLUE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BLUE, but not buy additional shares or sell existing shares. View BLUE analyst ratings or view top-rated stocks. What is bluebird bio's stock price target for 2024? 11 Wall Street research analysts have issued 12-month price targets for bluebird bio's stock. Their BLUE share price targets range from $1.02 to $13.00. On average, they predict the company's share price to reach $5.74 in the next year. This suggests a possible upside of 538.4% from the stock's current price. View analysts price targets for BLUE or view top-rated stocks among Wall Street analysts. How have BLUE shares performed in 2024? bluebird bio's stock was trading at $1.38 at the beginning of the year. Since then, BLUE shares have decreased by 34.8% and is now trading at $0.8998. View the best growth stocks for 2024 here. Are investors shorting bluebird bio? bluebird bio saw a increase in short interest in April. As of April 15th, there was short interest totaling 32,620,000 shares, an increase of 9.6% from the March 31st total of 29,750,000 shares. Based on an average trading volume of 8,500,000 shares, the days-to-cover ratio is currently 3.8 days. View bluebird bio's Short Interest. When is bluebird bio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our BLUE earnings forecast. How were bluebird bio's earnings last quarter? bluebird bio, Inc. (NASDAQ:BLUE) announced its quarterly earnings data on Tuesday, November, 7th. The biotechnology company reported ($0.66) EPS for the quarter, topping the consensus estimate of ($0.69) by $0.03. The biotechnology company had revenue of $12.40 million for the quarter, compared to analyst estimates of $13.56 million. bluebird bio had a negative net margin of 419.64% and a negative trailing twelve-month return on equity of 34.32%. bluebird bio's quarterly revenue was up 17364.8% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.92) EPS. What ETFs hold bluebird bio's stock? ETFs with the largest weight of bluebird bio (NASDAQ:BLUE) stock in their portfolio include Direxion Moonshot Innovators ETF (MOON) and Horizon Kinetics Medical ETF (MEDX).Global X Genomics & Biotechnology ETF (GNOM). What is Nick Leschly's approval rating as bluebird bio's CEO? 91 employees have rated bluebird bio Chief Executive Officer Nick Leschly on Glassdoor.com. Nick Leschly has an approval rating of 74% among the company's employees. What other stocks do shareholders of bluebird bio own? Based on aggregate information from My MarketBeat watchlists, some companies that other bluebird bio investors own include OPKO Health (OPK), BioMarin Pharmaceutical (BMRN), Puma Biotechnology (PBYI), NVIDIA (NVDA), Gilead Sciences (GILD), Incyte (INCY), Micron Technology (MU), Alibaba Group (BABA) and (MDVN) (MDVN). Who are bluebird bio's major shareholders? bluebird bio's stock is owned by many different retail and institutional investors. Top institutional shareholders include Mirae Asset Global Investments Co. Ltd. (0.30%), BNP Paribas Financial Markets (0.09%), Sequoia Financial Advisors LLC (0.04%), China Universal Asset Management Co. Ltd. (0.03%), Enterprise Bank & Trust Co (0.03%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Andrew Obenshain, Anne-Virginie Eggimann, Christopher Krawtschuk, Jason Cole, Jessica Whitten, Nick Leschly, Richard A Colvin and Thomas J Klima. View institutional ownership trends. How do I buy shares of bluebird bio? Shares of BLUE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:BLUE) was last updated on 5/4/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldCould Your Accounts Be Frozen?Allegiance GoldAutomatic Income (from home)Awesomely, LLCUrgent Nvidia WarningAltimetryGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchJeff Bezos Just Humiliated Elon MuskInvestorPlaceForget Nvidia. This is the future of AIPorter & CompanyThe asset beating inflation by 4xColonial Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding bluebird bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.